KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Takeda Pharmaceutical (TAK) Shares Outstanding (Weighted Average) (2018 - 2026)

Takeda Pharmaceutical has reported Shares Outstanding (Weighted Average) over the past 9 years, most recently at $776.34 for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) rose 73.26% year-over-year to $776.34; the TTM value through Mar 2026 reached $776.34, up 73.26%, while the annual FY2026 figure was $808.81, 80.23% up from the prior year.
  • Shares Outstanding (Weighted Average) was $776.34 for Q1 2026 at Takeda Pharmaceutical, up from $448.07 in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $11.3 billion in Q1 2024 and bottomed at $448.07 in Q1 2025.
  • The 5-year median for Shares Outstanding (Weighted Average) is $12.0 million (2023), against an average of $2.3 billion.
  • Year-over-year, Shares Outstanding (Weighted Average) skyrocketed 94476.66% in 2024 and then crashed 100.0% in 2025.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $13.6 million in 2022, then decreased by 12.14% to $12.0 million in 2023, then skyrocketed by 94476.66% to $11.3 billion in 2024, then crashed by 100.0% to $448.07 in 2025, then surged by 73.26% to $776.34 in 2026.
  • The last three reported values for Shares Outstanding (Weighted Average) were $776.34 (Q1 2026), $448.07 (Q1 2025), and $11.3 billion (Q1 2024) per Business Quant data.